The implant is the first biodegradable, intracameral implant approved by the FDA. It reduces intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The implant eliminates the need for daily eye drops, because it is a sustained-release drug delivery system.
More articles on specialty care:
ASC considers in-house alternative to ‘overwhelmed’ hospital testing center — 3 insights
425 surgery centers that received PPP funds of more than $150K by state
4 COVID-19 testing insights for ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.